Janux Therapeutics Inc. JANX
$13.73
▼ -0.73% 24H
About
Janux Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies for cancer and autoimmune diseases. It pioneers next-generation T cell engagers using proprietary TRACTr, TRACIr, and ARM platforms to create drug candidates that selectively activate immune responses i…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees108
TickerJANX
Statistics
Market Cap$835.7M
Revenue (TTM)$10.0M
Net Income-$113.6M
Net Margin-1136.3%
EPS$-1.83
P/E-7.46
P/S60.48
P/B0.88
EV/EBITDA0.67
ROE-11.7%
Dividend Yield—
Price$13.73
Data: Twelve Data · Revenue = mcap / P/S